Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome

Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the mainstay of therapy for patients with symptoms of restless legs syndrome (RLS). This study was designed to evaluate the factors affecting the efficacy of pramipexole in patients with RLS. Fifty-nine eligi...

Full description

Bibliographic Details
Main Authors: Mohammad Rezvani, Babak Zamani, Seyed-Mohammad Fereshtehnejad
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2013-06-01
Series:Acta Medica Iranica
Subjects:
Online Access:http://acta.tums.ac.ir/index.php/acta/article/view/4982/4387
id doaj-c9cae29adb874ef2bf2d0a06678d0234
record_format Article
spelling doaj-c9cae29adb874ef2bf2d0a06678d02342020-11-25T04:03:53ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942013-06-01516377385Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs SyndromeMohammad RezvaniBabak ZamaniSeyed-Mohammad FereshtehnejadDopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the mainstay of therapy for patients with symptoms of restless legs syndrome (RLS). This study was designed to evaluate the factors affecting the efficacy of pramipexole in patients with RLS. Fifty-nine eligible RLS patients referred to neurology clinic of Rasoul-e-Akram Hospital (Tehran, Iran) were recruited in this study. All of the patients received an oral dose of 0.18 mg pramipexole. The severity of RLS symptoms were evaluated including sleep disorder, symptomatic days per week and symptomatic hours per day, both at the beginning and at the end of follow-up time. Different baseline and follow-up variables were also recorded and their relationships with the outcomes were assessed. The mean severity values of different symptoms significantly decreased after treatment with pramipexole (P<0.001). Female gender (P<0.05) and duration of treatment (P<0.05) were significant factors to achieve >50% reduction in symptomatic days per week and symptomatic hours per day. Moreover, the cutoff point of 3.5 mo for duration of treatment could potentially differentiate >50% reduction in severity of sleep disorder from the ones with <50% reduction with sensitivity and specificity of 56.8% and 78.6%, respectively. Our findings show that female gender and duration of treatment were the factors affecting the effectiveness of pramipexole in RLS patients. If tolerated by the patients, a longer duration of treatment with pramipexole is more effective in RLS.http://acta.tums.ac.ir/index.php/acta/article/view/4982/4387EfficacyPramipexoleRestless Legs Syndrome (RLS)Treatment
collection DOAJ
language English
format Article
sources DOAJ
author Mohammad Rezvani
Babak Zamani
Seyed-Mohammad Fereshtehnejad
spellingShingle Mohammad Rezvani
Babak Zamani
Seyed-Mohammad Fereshtehnejad
Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome
Acta Medica Iranica
Efficacy
Pramipexole
Restless Legs Syndrome (RLS)
Treatment
author_facet Mohammad Rezvani
Babak Zamani
Seyed-Mohammad Fereshtehnejad
author_sort Mohammad Rezvani
title Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome
title_short Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome
title_full Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome
title_fullStr Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome
title_full_unstemmed Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome
title_sort factors affecting the efficacy of pramipexole in patients with restless legs syndrome
publisher Tehran University of Medical Sciences
series Acta Medica Iranica
issn 0044-6025
1735-9694
publishDate 2013-06-01
description Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the mainstay of therapy for patients with symptoms of restless legs syndrome (RLS). This study was designed to evaluate the factors affecting the efficacy of pramipexole in patients with RLS. Fifty-nine eligible RLS patients referred to neurology clinic of Rasoul-e-Akram Hospital (Tehran, Iran) were recruited in this study. All of the patients received an oral dose of 0.18 mg pramipexole. The severity of RLS symptoms were evaluated including sleep disorder, symptomatic days per week and symptomatic hours per day, both at the beginning and at the end of follow-up time. Different baseline and follow-up variables were also recorded and their relationships with the outcomes were assessed. The mean severity values of different symptoms significantly decreased after treatment with pramipexole (P<0.001). Female gender (P<0.05) and duration of treatment (P<0.05) were significant factors to achieve >50% reduction in symptomatic days per week and symptomatic hours per day. Moreover, the cutoff point of 3.5 mo for duration of treatment could potentially differentiate >50% reduction in severity of sleep disorder from the ones with <50% reduction with sensitivity and specificity of 56.8% and 78.6%, respectively. Our findings show that female gender and duration of treatment were the factors affecting the effectiveness of pramipexole in RLS patients. If tolerated by the patients, a longer duration of treatment with pramipexole is more effective in RLS.
topic Efficacy
Pramipexole
Restless Legs Syndrome (RLS)
Treatment
url http://acta.tums.ac.ir/index.php/acta/article/view/4982/4387
work_keys_str_mv AT mohammadrezvani factorsaffectingtheefficacyofpramipexoleinpatientswithrestlesslegssyndrome
AT babakzamani factorsaffectingtheefficacyofpramipexoleinpatientswithrestlesslegssyndrome
AT seyedmohammadfereshtehnejad factorsaffectingtheefficacyofpramipexoleinpatientswithrestlesslegssyndrome
_version_ 1724438792509587456